Meta-análisis de la asociación entre las variantes VAL66MET de BDNF, 2/3/4 de APOE y la esquizofrenia
Meta-analysis of the association between the VAL66MET variants of BDNF, 2/3/4 of APOE and the schizophrenia
Abstract (en)
Schizophrenia is a mental disorder based on multiple factors, so the etiology is still under discussion; many candidates have been identified as genetic risk factors to the phenotype, including the postulates in the meta-analysis. APOE gene codes for a protein involved in the transport of lipids being the variable candidate e4 important risk factor for schizophrenia and polymorphism VAL66MET BDNF involved in intercellular secretion alterations in the neurotrophin, postulated in association with the disorder. A systematic review was conducted through various databases, compiling 25 case-control studies related to the association of some of the variables to schizophrenia, under strict eligibility criteria, among them meta-analytic association was determined using the random effects model, for inferring the impact of the risk allele and the genotype at schizophrenia. It was obtained a slight association of the e4 variant in Caucasians. On the other hand neither the Met genotype carrier, neither allele Met have showed a significant association to phenotype, these results contrast the many contradictory studies published in recent years, thus generating overall result of the influence of genotype variants.Abstract (es)
La esquizofrenia es un trastorno mental de tipo multifactorial, por lo que su etiología aún sigue en discusión, se han determinado diversos candidatos como factores de riesgo genético al fenotipo, entre ellos los postulados en el meta-análisis, el gen APOE codifica para una proteína implicada en el trasporte de lípidos, siendo la variable e4 candidata importante a factor de riesgo para la esquizofrenia, y el polimorfismo BNDF VAL66MET implicado en alteraciones de secreción intercelular en la neurotrofina, postulado en la asociación con el trastorno. Se realizó una revisión sistemática a través de diversas bases de datos, compilando 25 estudios caso-control relacionados con la asociación de alguna de las variables a la esquizofrenia, bajo estrictos criterios de elegibilidad, a partir de ellos se determinó la asociación meta-analítica utilizando el modelo de efectos aleatorios, infiriendo la incidencia del alelo de riesgo y el genotipo portador del mismo a la esquizofrenia. Se encontró una leve asociación de la variante e4 en la etnia caucásica, por otra parte, ni el alelo Met ni el genotipo portador reflejó una asociación significativa al fenotipo, estos resultados contrastan la gran cantidad de estudios contradictorios publicados en los últimos años, estableciendo un resultado global acerca de la influencia de las variantes con el genotipo.
References
Barrera A. (2006). Los trastornos cognitivos de la esquizofrenia. Rev Chil Neuropsiquiatr. [fecha de acceso 10 de enero de 2016], 44(3), 215-221. URL disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-92272006000300007&lng=es&tlng=es. 10.4067/S0717-92272006000300007.
Begg C, Mazumdar M. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 1088-1101.
Chen S, Lee S, Chang Y, Chen S, Chu C, Wang T, et al. (2014). The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 51, 99-104.
Corbo, R. M., & Scacchi, R. (1999). Apolipoprotein E (APOE) allele distribution in the world. Is APOE* 4 a ‘thrifty’allele? Annals of human genetics, 63(4), 301-310.
Dean B, Laws S, Hone E, Taddei K, Scarr E, Thomas E, et al. (2003). Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry, 54(6), 616-622.
DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials, 7(3), 177– 188.
Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 112(2), 257–269.
Evans J, Chua S, McKenna P, Wilson B. (1997). Assessment of the dysexecutive syndrome in schizophrenia. Psychol Med, 27(03), 635-646.
Forero, D. A., & Sánchez-Contreras, M. (2008). Genética molecular y psiquiatría: de los síntomas a los mecanismos. [fecha de acceso 20 de noviembre de 2016]. URL disponible en: http://users.skynet.be/dforero/chapter.pdf.
Galbraith R. (1988). A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med, 7, 889-94.
Gejman, P. V., & Sanders, A. R. (2012). La etiología de la esquizofrenia. Medicina (Buenos Aires), 72(3), 227-234.
Golimbet V, Korovaitseva G, Abramova L, Kasparov S, Uvarova, L. (2008). Association of the Val66Met polymorphism of the brain-derived neurotrophic factor gene with schizophrenia in Russians. Mol Biol, 42(4), 531-535.
González-Giraldo, Y., Rojas, J., Novoa, P., Mueller, S. T., Piper, B. J., Adan, A., & Forero, D. A. (2014). Functional polymorphisms in BDNF and COMT genes are associated with objective differences in arithmetical functioning in a sample of young adults. Neuropsychobiology, 70(3), 152-157.
Gottesman I, Bertelsen A. (1989). Confirming unexpressed genotypes for schizophrenia: risks in the offspring of Fischer's Danish identical and fraternal discordant twins. Arch Gen Psychiatry, 46(10), 867-872.
Gratacòs M, González J, Mercader J, de Cid R, Urretavizcaya M, Estivill X. (2007). Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirms association to substance-related disorders, eating disorders and schizophrenia. Biol Psychiatry, 61(7), 911-922.
Hallman D, Boerwinkle E, Saha N, Sandholzer C, Menzel H, Csazar A, Utermann G. (1991) The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet, 49(2): 338.
Harrington C, Roth M, Xuereb J, McKenna P, Wischik C. (1995). Apolipoprotein E type ϵ4 allele frequency is increased in patients with schizophrenia. Neurosci Lett, 202(1), 101-104.
Igata-Yi R, Igata T, Ishizuka K, Kimura T, Sakamoto S, Katsuragi S, et al. (1997) Apolipoprotein E genotype and psychosis. Biol Psychiatry, 41(8), 906-908.
Jablensky, A. (1999). The concept of schizophrenia: pro et contra. Epidemiologia e psichiatria sociale, 8, 242-247.
Jablensky, A. (2000). Epidemiology of schizophrenia: the global burden of disease and disability. European archives of psychiatry and clinical neuroscience, 250(6), 274-285.
Kayahan B, Kaymaz B, Altıntoprak A, Aktan Ç, Veznedaroğlu B, Kosova B. (2013). The lack of association between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms and schizophrenia in a group of Turkish population. Neurol Psychiatry Brain Res, 19(3), 102-108.
Kirkbride J, Susser E, Kundakovic M, Kresovich J, Davey Smith G, Relton C. (2012). Prenatal nutrition, epigenetics and schizophrenia risk: can we test causal effects? Epigenomics, 4(3), 303-315.
Lan T, Hong C, Chen J, Sim C. Apolipoprotein E-epsilon 4 frequency in patients with schizophrenia. Biol Psychiatry, 42(3), 225.
Lee M, Park A, Nam B, Min K, Kee B, Park D. (2001). Apolipoprotein E genotype in Korean schizophrenic patients. J Korean Med Sci, 16(6), 781.
Liu W, Breen G, Zhang J, Li S, Gu N, Feng G, He L, et al. (2003), Association of APOE gene with schizophrenia in Chinese: a possible risk factor in times of malnutrition. Schizophrenia research, 62(3), 225-230.
Lu W, Zhang C, Yi Z, Li Z, Wu Z, Fang Y. (2012). Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J Mol Neurosci, 47(3), 505-510.
Mahley R. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Sci, 240(4852), 622-630.
Martorell L, Virgos C, Valero J, Coll G, Figuera L, Joven J, Vilella E, et al. (2001). Schizophrenic women with the APOE epsilon 4 allele have a worse prognosis than those without it. Mol Psychiatry, 6(3), 307-310.
Moberg P, Arnold S, Roalf D, Balderston C, Abbazia J, Kohler C, et al. (2006). Apolipoprotein E genotype and odor identification in schizophrenia. J Neuropsychiatry Clin Neurosci, 18(2), 231-233.
Neves-Pereira M, Cheung J, Pasdar A, Zhang F, Breen G, Yates P, et al. (2005). BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry, 10(2), 208-212.
Olkin I. (1995). Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol, 48(1), 133-146.
Pardo V. (2005). Trastornos cognitivos en la esquizofrenia I. Estudios cognitivos en pacientes esquizofrénicos: puesta al día. Rev Psiquiatr Urug, 69(1), 71-83.
Rodríguez, J. M. (2002). Factores de riesgo en la esquizofrenia. Informaciones psiquiátricas: Publicación científica de los Centros de la Congregación de Hermanas Hospitalarias del Sagrado Corazón de Jesús, 169(2).
Sagoo G, Little J, Higgins J. (2009). Systematic reviews of genetic association studies. PLoS Med. 6(3): e1000028.
Santiago P, Hervada V, Naveira B, Silva L, Fariñas H, Vázquez E, et al. (2010). El programa epidat: usos y perspectivas. Rev Panam Salud Pública, 27(1), 80-82.
Seidah N, Benjannet S, Pareek S, Chrétien M, Murphy R. (1996). Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett, 379(3), 247-250.
Setó-Salvia N, Clarimón J. (2010). Genética en la enfermedad de Alzheimer. Rev Neurol, 50(6), 360-364.
Shimabukuro M, Sasaki T, Imamura A, Tsujita T, Fuke C, Umekage T, et al. (2007). Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J Psychiatr Res, 41(12), 1042-1046.
Sitskoorn M, Aleman A, Ebisch S, Appels M, Kahn R. (2004). Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis.
Schizophr Res, 71(2), 285-295.
Sorbi S, Nacmias B, Tedde A, Latorraca S, Forleo P, Guarnieri, B, et al. (1998). No implication of apolipoprotein E polymorphism in Italian schizophrenic patients. Neurosci Lett, 244(2), 118-120.
Sotiropoulou M, Mantas C, Bozidis P, Marselos M, Mavreas V, Hyphantis T. (2013). BDNF serum concentrations in first psychotic episode drug-naive schizophrenic patients: associations with personality and BDNF Val66Met polymorphism. Life Sci, 92(4), 305-310.
Suchanek R, Owczarek A, Paul-Samojedny M, Kowalczyk M, Kucia K, Kowalski J. (2013). BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci, 25(1), 88-94.
Sµiz P, Morales B, G-Portilla M, Alvarez V, Coto E, Fernµndez J, et al. (2002). Apolipoprotein E genotype and schizophrenia: further negative evidence. Acta Psychiatr Scand, 105, 71-75.
Takahashi T, Suzuki M, Tsunoda M, Kawamura Y, Takahashi N, Tsuneki H, et al. (2008). Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons. Neuro Lett, 435(1), 34-39.
Thibaut F, Van Der Elst A, Campion D, Martin C, Coron B, Dollfus S, et al. (1999) Apolipoprotein E-ε 4 frequency in deficit schizophrenia. Eur Psychiatry, 14(3), 148-151.
Tochigi M, Otowa T, Suga M, Rogers M, Minato T, Yamasue H, et al. (2006). No evidence for an association between the BDNF Val66Met polymorphism and schizophrenia or personality traits. Schizophr Res, 87(1), 45-47.
Tovilla-Zárate, C., Camarena, B., Apiquianc, R., & Nicolinia, H. (2008). Estudio de asociación y metaanálisis del gen de la apolipoproteína E y esquizofrenia. Gac Méd Méx, 144(2), 79.
Urrútia, G., & Bonfill, X. (2010). Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Med clin, 135(11), 507-511.
Utermann G. (1989). The mysteries of lipoprotein (a). Sci, 246(4932), 904-910.
Vila-Rodriguez F, Honer W, Innis S, Wellington C, Beasley C. (2011). ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype. J Psychiatry Neurosci, 36(1), 47.
Wisdom N, Callahan J, Hawkins K. (2011). The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Schizophr Res, 32(1), 63-74.
Xu M, St Clair D, He L. (2006). Meta-analysis of association between ApoE ε4 allele and schizophrenia. Schizophr Res, 84(2), 228-235.
Yang Y, Kim J, Park S, Kim S, Jeon O, Kim D. (2007). Apolipoprotein E genotyping by multiplex tetra-primer amplification refractory mutation system PCR in single reaction tube. Journal of biotechnology, 131(2), 106-110.
Yi Z, Zhang C, Wu Z, Hong W, Li Z, Fang Y, et al. (2011). Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Res, 1417, 146-150.
Zhang XY, Xiu MH, Haile CN, Luo X, Xu K, Zhang H, et al. (2012). Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet, 131(7), 1187-1195.
Zhou D, Yan Q, Yan X, Li C, Fang H, Zheng Y, et al. (2010). The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry, 34(6), 930-933.
How to Cite
License
The authors sign a transfer of rights so that Universidad Santo Tomás can publish the articles under the conditions described below. The authors, readers and other users are free to share, copy, distribute, perform and publicly communicate the work under the following conditions:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
CITAS is licensed under Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
Until 2019 the documents published in the magazine were under the Creative Commons Attribution-ShareAlike license (CC BY-SA), however, in order to guarantee the open and free distribution of the content published in the magazine, it was decided to change the type Commons Attribution-NonCommercial-ShareAlike 4.0 International license (CC BY-NC-SA 4.0)
